Immunizations
Appointments are not required. Check-in is located at the Readiness Clinic front desk, across from the Pharmacy. After checking in, bring your screening forms to the Immunization Clinic window. You will be directed to wait in the Immunization Clinic waiting area for your name to be called.
Standard immunizations, including influenza, are available on a walk-in basis.
Eligibility
- Active Duty
- Beneficiaries (Pediatric/Adolescent patients must be enrolled at Andrew Rader)
- Retirees
- Occupational Health Patients
- Active Guard Reserve
Flu Vaccine
We encourage everyone to get vaccinated annually against influenza. It’s critical for everyone who is able to receive a flu vaccine. It’s essential that active duty service members, active duty family members and other beneficiaries are well-protected from influenza.
All beneficiaries can check with their military clinic locations for vaccination availability. Beneficiaries may also go to any TRICARE retail network pharmacy to be vaccinated at no cost. Find an eligible pharmacy near you at:
Military Express Scripts..
COVID-19 Vaccine
COVID-19 vaccines are not available at Rader Army Health Clinic.
Check with local retail pharmacies in the TRICARE network for availability and how to schedule an appointment to get the vaccine. Visit the CDC website for more information.
Tuberculosis Placement and Screening
Your provider must enter a prescription referral to administer the placement test. After placement, all patients must return to the immunization clinic no earlier than 48 and no later than 72 hours to have the test read.
Respiratory Syncytial Virus (RSV)
RSV is a common respiratory virus that typically causes mild cold-like symptoms, with usual recovery in a week or two. However, RSV can cause more severe illness especially for infants and adults 60 years and older with chronic heart or lung disease, or who have weakened immune systems.
Talk to your health care provider to see if vaccination is right for you. All RSV vaccines require prescription (provider referral) before administration.
- Nirsevimab (Beyfortus) is the new monoclonal antibody for RSV prophylaxis which was approved by the FDA in July 2023 for administration to all infants 8 months and younger entering their first RSV season.
- RSVPreF3 (Arexvy) and RSVpreF (ABRYSVO) are approved for active immunization of individuals 60 years and older with shared clinical decision-making.
- RSVpreF (ABRYSVO) is also approved for active immunization of pregnant individuals at 32 through 36 weeks gestational age using seasonal administration (September through January in most of the continental United States) for the prevention of RSV infection in infants from birth through 6 months of age via maternal transfer of passive antibody to the infant in utero.
More information about RSV can be found on the CDC page.